> top > docs > PubMed:23184608 > annotations

PubMed:23184608 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T3 48-72 D002285 denotes ductal carcinoma in situ
T4 48-72 D002285 denotes ductal carcinoma in situ
T9 78-82 PR:P15379 denotes CD44
T10 78-82 PR:P26051 denotes CD44
T11 78-82 PR:000001307 denotes CD44
T12 78-82 PR:P16070 denotes CD44
T13 94-104 D000906 denotes antibodies
T14 108-112 PR:000005054 denotes mice
T16 108-112 O89094 denotes mice
T15 108-112 D051379 denotes mice
T17 108-112 10095 denotes mice
T20 242-266 D002285 denotes ductal carcinoma in situ
T21 242-266 D002285 denotes ductal carcinoma in situ
T27 268-272 CVCL_5552 denotes DCIS
T26 268-272 D002285 denotes DCIS
T28 268-272 D002285 denotes DCIS
T29 303-315 GO:0051179 denotes localization
T31 319-323 CVCL_5552 denotes DCIS
T30 319-323 D002285 denotes DCIS
T32 319-323 D002285 denotes DCIS
T33 343-347 PR:P15379 denotes CD44
T34 343-347 PR:P26051 denotes CD44
T35 343-347 PR:000001307 denotes CD44
T36 343-347 PR:P16070 denotes CD44
T38 377-381 CVCL_5552 denotes DCIS
T37 377-381 D002285 denotes DCIS
T39 377-381 D002285 denotes DCIS
T40 427-431 PR:P15379 denotes CD44
T41 427-431 PR:P26051 denotes CD44
T42 427-431 PR:000001307 denotes CD44
T43 427-431 PR:P16070 denotes CD44
T44 444-454 D000906 denotes antibodies
T46 472-476 CVCL_5552 denotes DCIS
T45 472-476 D002285 denotes DCIS
T47 472-476 D002285 denotes DCIS
T48 489-493 PR:000005054 denotes Mice
T50 489-493 O89094 denotes Mice
T49 489-493 D051379 denotes Mice
T51 489-493 10095 denotes Mice
T52 530-534 PR:P15379 denotes CD44
T53 530-534 PR:P26051 denotes CD44
T54 530-534 PR:000001307 denotes CD44
T55 530-534 PR:P16070 denotes CD44
T57 546-555 CVCL_5552 denotes MCF10DCIS
T58 551-555 D002285 denotes DCIS
T60 551-555 D002285 denotes DCIS
T62 556-560 CVCL_5552 denotes DCIS
T61 556-560 D002285 denotes DCIS
T63 556-560 D002285 denotes DCIS
T64 566-572 D009369 denotes tumors
T65 566-572 D009369 denotes tumors
T66 577-581 PR:P15379 denotes CD44
T67 577-581 PR:P26051 denotes CD44
T68 577-581 PR:000001307 denotes CD44
T69 577-581 PR:P16070 denotes CD44
T70 593-596 CHEBI:566274 denotes MDA
T71 593-603 CVCL_0062 denotes MDA-MB-231
T73 612-618 D009369 denotes tumors
T74 612-618 D009369 denotes tumors
T77 652-662 C562366 denotes IRDye800CW
T78 652-662 C562366 denotes IRDye800CW
T79 677-681 PR:P15379 denotes CD44
T80 677-681 PR:P26051 denotes CD44
T81 677-681 PR:000001307 denotes CD44
T82 677-681 PR:P16070 denotes CD44
T83 693-703 D000906 denotes antibodies
T84 915-919 PR:P15379 denotes CD44
T85 915-919 PR:P26051 denotes CD44
T86 915-919 PR:000001307 denotes CD44
T87 915-919 PR:P16070 denotes CD44
T88 931-941 D000906 denotes antibodies
T89 983-988 D009369 denotes tumor
T90 983-988 D009369 denotes tumor
T92 1013-1022 CVCL_5552 denotes MCF10DCIS
T93 1018-1022 D002285 denotes DCIS
T95 1018-1022 D002285 denotes DCIS
T96 1023-1029 D009369 denotes tumors
T97 1023-1029 D009369 denotes tumors
T99 1076-1082 D009369 denotes tumors
T100 1076-1082 D009369 denotes tumors
T109 1119-1122 D007074 denotes IgG
T110 1171-1176 D009369 denotes tumor
T111 1171-1176 D009369 denotes tumor
T113 1351-1355 CVCL_5552 denotes DCIS
T112 1351-1355 D002285 denotes DCIS
T114 1351-1355 D002285 denotes DCIS
T115 1383-1387 PR:P15379 denotes CD44
T116 1383-1387 PR:P26051 denotes CD44
T117 1383-1387 PR:000001307 denotes CD44
T118 1383-1387 PR:P16070 denotes CD44
T119 1399-1409 D000906 denotes antibodies

Allie

Id Subject Object Predicate Lexical cue
SS1_23184608_2_0 242-266 expanded denotes ductal carcinoma in situ
SS2_23184608_2_0 268-272 abbr denotes DCIS
AE1_23184608_2_0 SS1_23184608_2_0 SS2_23184608_2_0 abbreviatedTo ductal carcinoma in situ,DCIS

UseCases_ArguminSci_Discourse

Id Subject Object Predicate Lexical cue
T1 0-134 DRI_Background denotes Near-infrared fluorescence molecular imaging of ductal carcinoma in situ with CD44v6-specific antibodies in mice: a preclinical study.
T2 144-339 DRI_Background denotes The purpose of this study was to develop a molecular imaging technique using tracers specific for ductal carcinoma in situ (DCIS) to improve visualization and localization of DCIS during surgery.
T3 340-477 DRI_Background denotes As CD44v6 is frequently expressed in DCIS, we used near-infrared fluorescently labeled CD44v6-targeting antibodies for detection of DCIS.
T4 489-529 DRI_Background denotes Mice bearing orthotopically transplanted
T5 530-565 Token_Label.OUTSIDE denotes CD44v6-positive MCF10DCIS DCIS-like
T6 566-576 DRI_Background denotes tumors and
T7 577-603 Token_Label.OUTSIDE denotes CD44v6-negative MDA-MB-231
T8 604-720 DRI_Background denotes control tumors were intravenously injected with IRDye800CW conjugated to CD44v6-specific antibodies or control IgGs.
T9 721-816 DRI_Background denotes Noninvasive imaging was performed for 8 days postinjection, followed by intraoperative imaging.
T10 817-881 DRI_Background denotes Antibody accumulation and intratumor distribution were examined.
T11 891-974 DRI_Approach denotes Maximum accumulation of CD44v6-specific antibodies was obtained 24 h postinjection.
T12 975-1161 DRI_Approach denotes Maximum tumor-to-background ratio for MCF10DCIS tumors was 4.5 ± 0.2, compared to 1.4 ± 0.1 (control tumors, p = 0.006), and 1.7 ± 0.1 (control IgG, p = 0.014), for 8 days postinjection.
T13 1162-1258 DRI_Background denotes Ex vivo, tumor-to-background ratios were comparable to those obtained by intraoperative imaging.
T14 1272-1410 DRI_Outcome denotes We show the applicability of noninvasive and intraoperative optical imaging of DCIS-like lesions in vivo using CD44v6-specific antibodies.

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 144-477 OBJECTIVE denotes The purpose of this study was to develop a molecular imaging technique using tracers specific for ductal carcinoma in situ (DCIS) to improve visualization and localization of DCIS during surgery. As CD44v6 is frequently expressed in DCIS, we used near-infrared fluorescently labeled CD44v6-targeting antibodies for detection of DCIS.
T2 489-881 METHODS denotes Mice bearing orthotopically transplanted CD44v6-positive MCF10DCIS DCIS-like tumors and CD44v6-negative MDA-MB-231 control tumors were intravenously injected with IRDye800CW conjugated to CD44v6-specific antibodies or control IgGs. Noninvasive imaging was performed for 8 days postinjection, followed by intraoperative imaging. Antibody accumulation and intratumor distribution were examined.
T3 891-1258 RESULTS denotes Maximum accumulation of CD44v6-specific antibodies was obtained 24 h postinjection. Maximum tumor-to-background ratio for MCF10DCIS tumors was 4.5 ± 0.2, compared to 1.4 ± 0.1 (control tumors, p = 0.006), and 1.7 ± 0.1 (control IgG, p = 0.014), for 8 days postinjection. Ex vivo, tumor-to-background ratios were comparable to those obtained by intraoperative imaging.
T4 1272-1410 CONCLUSIONS denotes We show the applicability of noninvasive and intraoperative optical imaging of DCIS-like lesions in vivo using CD44v6-specific antibodies.